PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
259.8K views | +223 today
Follow

JNJ Innovation Aims to Develop Breakthrough Medical Device Technologies

From www.jnjinnovation.com

Johnson & Johnson Innovation LLC (JJI) today announced the creation of the Center for Device Innovation at Texas Medical Center (CDI @ TMC), a broad, new collaboration between JJI and TMC that aims to accelerate end-to-end development of breakthrough medical devices. This expands on JJI’s collaboration with TMC established earlier this year with the opening of JLABS @ TMC, combining the resources of the world’s largest medical complex with the capabilities of the Johnson & Johnson Medical Devices Companies*, to advance the health and well-being of people around the globe.

 

The CDI @ TMC will include multiple components that will accelerate the development of new medical technologies from concept through commercialization, including a new medical device engineering studio housed at the TMC Innovation Institute. This state-of-the-art “maker space” will be home to R&D staff of the Johnson & Johnson Medical Devices Companies and will be used to accelerate both select internal projects and strategically aligned ventures of JJI partner companies.

Pharma Guy's curator insight, October 18, 2016 1:06 PM

Related article: “Johnson & Johnson Expands Its Membership in the Digital Innovation Club”; http://sco.lt/65ScEr

Les pansements aussi deviennent intelligents - Les Echos

From www.lesechos.fr

Urgo, numéro 3 européen dans les pansements, travaille au développement de sparadraps high-tech pour accélérer la cicatrisation des plaies chroniques. Une innovation médicalement et économiquement prometteuse.

No comment yet.

Sometimes #Pharma "Innovation" Doesn't Make Good Business Sense: Merck/Diabetes Case Study

From www.pmlive.com

Merck & Co will no longer file for approval of once-weekly diabetes drug omarigliptin in the US or Europe.


The company said in a statement that the decision did not relate to any safety or efficacy issues with the DPP-4 inhibitor, which might suggest it is not confident that the market is prepared to pay a premium for a weekly compared to a once-daily drug such as Merck's own Januvia (sitagliptin) product.


There are thought to be other issues with once-weekly administration of DPP-4 inhibitors. While they are intended to reduce the burden of taking pills by diabetics and improve compliance, patients can rarely benefit from drug-free days as those on DPP-4 inhibitors often also take metformin, which must be dosed every day.


Some clinicians argue that it is easier for patients to keep track of dosing two drugs side by side rather than mixing weekly and daily doses.

No comment yet.

Takeda Joins #Pharma Digital Accelerator Club

From www.pharmexec.com

Global pharma company Takeda is another example of a leading company that is pursuing new applications of digital technology to develop solutions to the challenges facing healthcare, both here in Japan and around the world.
 
Takeda and its “Start-Up Incubator”
With more than 30,000 employees, a presence in 70 countries and products across a wide range of therapeutic areas, Takeda is constantly looking for new ways to bring new value to patients as part of its patient-centric culture. One of these ways is its approach to digital strategy and technology.
 
Takeda has embedded digital strategy into its DNA with a model it calls the "Takeda Digital Accelerator”," designed to provide investment to new ideas that apply key customer digital trends to the healthcare space, with the goal of generating patient-centric innovations that can drive stronger outcomes. Its foundation is in digital experimentation, where new ways of thinking and working are discovered by testing and learning.
 
First, Takeda assembles the teams and resources needed for this experimentation to take place. Then, different teams work on small, local challenges, which they test using specific hypothesis. These findings are then incubated and shared acros the Takeda community, where other teams can leverage them.
 
Another way this Digital Accelerator model works is through the global ecosystem of external partners Takeda has built over the years. These partners are also helpe make recommendations and solutions to healthcare challenges, and the findings are incubated, tested and shared across the larger network.
 
This kind of forward thinking helps Takeda identify, explore and experiment with new ways of digitizing the healthcare experience in ways that ultimately benefit patients.
Lionel Reichardt / le Pharmageek:

My friend Craig DeLarge (@cadelarge), Head of Digital Acceleration, Emerging Markets at Takeda, must be involved in this. I invite him to be a guest on my podcast show!

Sandra Boyer's curator insight, March 12, 2016 5:41 PM

My friend Craig DeLarge (@cadelarge), Head of Digital Acceleration, Emerging Markets at Takeda, must be involved in this. I invite him to be a guest on my podcast show!

Helen Adams's curator insight, March 14, 2016 5:58 AM

My friend Craig DeLarge (@cadelarge), Head of Digital Acceleration, Emerging Markets at Takeda, must be involved in this. I invite him to be a guest on my podcast show!

Melanie COVINHES's curator insight, March 14, 2016 6:22 AM

My friend Craig DeLarge (@cadelarge), Head of Digital Acceleration, Emerging Markets at Takeda, must be involved in this. I invite him to be a guest on my podcast show!

Oct 12, 2011 | Multichannel innovation: 15 brilliant examples from 2011

From econsultancy.com

JUMP is a one-day conference in London on Oct 12, dedicated to 'helping you and your team be the best you possibly can' ;-). An annual event dedicated to multichannel business.

No comment yet.